Clinical Trial

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open label Phase 1, First in Human trial designed to evaluate the safety, tolerability pharmacokinetics, preliminary efficacy of BA1301 in participants with advanced solid tumors.
Trial Details
NCT Number NCT06927349
Lead Sponsor Shandong Boan Biotechnology Co., Ltd
Conditions Advanced Solid Tumours
Enrollment 70 participants
Start Date 2023-01-11
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-15